Immunic Inc. (IMUX)
12.91
-1.52 (10.53%)
Upcoming Events
Latest Headlines
Form 4 IMMUNIC, INC. For: May 22 Filed by: Lundgren Erik
June 1, 2026 5:57 PM - SEC Filing
Form 3 IMMUNIC, INC. For: Jun 01 Filed by: Lundgren Erik
June 1, 2026 5:56 PM - SEC Filing
Form DEF 14A IMMUNIC, INC. For: Jun 29
May 29, 2026 4:33 PM - SEC Filing
Form 8-K IMMUNIC, INC. For: May 28
May 28, 2026 7:01 AM - SEC Filing
Immunic presents additional data on multiple sclerosis drug candidate
May 28, 2026 6:30 AM - StreetInsider
Immunic presents phase 2 trial data at multiple sclerosis meeting
May 28, 2026 6:30 AM - StreetInsider
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
May 28, 2026 6:30 AM - PR NewsWire
Stifel on Immunic Inc. (IMUX): 'Overall, we see a number of potential avenues for differentiation for VidoCa'
May 27, 2026 8:43 AM - StreetInsider
Form 8-K IMMUNIC, INC. For: May 22
May 27, 2026 7:01 AM - SEC Filing
Immunic names Erik Lundgren as new chief executive officer
May 27, 2026 6:30 AM - StreetInsider
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
May 27, 2026 6:30 AM - PR NewsWire
Immunic Inc. (IMUX) PT Lowered to $27 at B.Riley
May 22, 2026 8:41 AM - StreetInsider
Wolfe Research Starts Immunic Inc. (IMUX) at Outperform, PT $25
May 22, 2026 5:49 AM - StreetInsider
Form 3 IMMUNIC, INC. For: May 16 Filed by: BONNEY MICHAEL W
May 19, 2026 5:36 PM - SEC Filing
Form 8-K IMMUNIC, INC. For: May 16
May 19, 2026 7:01 AM - SEC Filing
Immunic names Michael Bonney as board chair
May 19, 2026 6:31 AM - StreetInsider
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
May 19, 2026 6:30 AM - PR NewsWire
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Alyeska Investment Group, L.P.
May 15, 2026 4:42 PM - SEC Filing
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: 683 Capital Management, LLC
May 15, 2026 10:49 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Immunic Inc. (IMUX)
May 14, 2026 6:50 AM - StreetInsider
Form 8-K IMMUNIC, INC. For: May 13
May 13, 2026 7:01 AM - SEC Filing
Immunic Inc. (IMUX) Misses Q1 EPS by 100c
May 13, 2026 6:42 AM - StreetInsider
Form 10-Q IMMUNIC, INC. For: Mar 31
May 13, 2026 6:37 AM - SEC Filing
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026 6:30 AM - PR NewsWire
Form SCHEDULE 13G IMMUNIC, INC. Filed by: INTEGRATED CORE STRATEGIES (US) LLC
May 6, 2026 6:02 PM - SEC Filing
Form EFFECT IMMUNIC, INC.
May 5, 2026 6:07 AM - SEC Filing
Form S-3/A IMMUNIC, INC.
April 30, 2026 5:18 PM - SEC Filing
Immunic Inc. (IMUX) PT Raised to $22 at H.C. Wainwright
April 30, 2026 6:51 AM - StreetInsider
Immunic to Participate in Investor and Medical Conferences in May
April 30, 2026 6:30 AM - PR NewsWire
Form 4 IMMUNIC, INC. For: Apr 24 Filed by: Panzara Michael A.
April 29, 2026 7:15 AM - SEC Filing
Form 3 IMMUNIC, INC. For: Apr 24 Filed by: Panzara Michael A.
April 29, 2026 7:13 AM - SEC Filing
Form 8-K IMMUNIC, INC. For: Apr 24
April 28, 2026 7:01 AM - SEC Filing
Immunic names Michael Panzara as chief medical officer
April 28, 2026 6:30 AM - StreetInsider
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
April 28, 2026 6:30 AM - PR NewsWire
Form 8-K IMMUNIC, INC. For: Apr 22
April 23, 2026 8:31 AM - SEC Filing
Immunic implements 1-for-10 reverse stock split effective april 27
April 23, 2026 8:03 AM - StreetInsider
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
April 23, 2026 8:02 AM - PR NewsWire
Form 10-K/A IMMUNIC, INC. For: Dec 31
April 22, 2026 4:56 PM - SEC Filing
Form SCHEDULE 13G IMMUNIC, INC. Filed by: Avidity Partners Management LP
April 17, 2026 10:14 AM - SEC Filing
Stifel Starts Immunic Inc. (IMUX) at Buy
April 16, 2026 4:08 PM - StreetInsider
D. Boral Capital Downgrades Immunic Inc. (IMUX) to Hold
April 15, 2026 7:27 AM - StreetInsider
Form 8-K IMMUNIC, INC. For: Apr 14
April 14, 2026 4:05 PM - SEC Filing
Form 8-K IMMUNIC, INC. For: Apr 07
April 10, 2026 4:05 PM - SEC Filing
Form S-8 IMMUNIC, INC.
April 9, 2026 4:31 PM - SEC Filing
Immunic to Participate in Scientific and Medical Conferences in April
April 9, 2026 6:30 AM - PR NewsWire
Immunic Inc. (IMUX) files for 458.15M share offering by selling stockholders
April 2, 2026 4:34 PM - StreetInsider
Form S-3 IMMUNIC, INC.
April 2, 2026 4:32 PM - SEC Filing
Form 8-K IMMUNIC, INC. For: Mar 27
April 1, 2026 7:02 AM - SEC Filing
Immunic regains compliance with Nasdaq minimum bid price rule
April 1, 2026 6:30 AM - StreetInsider
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 1, 2026 6:30 AM - PR NewsWire
Form 3 IMMUNIC, INC. For: Mar 27 Filed by: Congleton Jon
March 31, 2026 4:01 PM - SEC Filing
Form 8-K IMMUNIC, INC. For: Mar 27
March 31, 2026 6:45 AM - SEC Filing
Immunic appoints Jon Congleton to board of directors
March 31, 2026 6:30 AM - StreetInsider
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
March 31, 2026 6:30 AM - PR NewsWire
Guggenheim Starts Immunic Inc. (IMUX) at Buy
March 24, 2026 4:31 AM - StreetInsider
Immunic receives European patent for vidofludimus calcium dosing regimens
March 10, 2026 6:30 AM - StreetInsider
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
March 10, 2026 6:30 AM - PR NewsWire
Full Article List
